Contact us

Our latest news

Back to news >

CellCentric’s first-in-class p300/CBP inhibitor CCS1477 publishes in Cancer Discovery

CellCentric have achieved a major milestone as CCS1477 publishes in Cancer Discovery: Targeting p300/CBP axis in lethal prostate cancer.

This is the result of a great collaboration with the Institute of Cancer Research, London and Sidney Kimmel Cancer Centre (TJU), Philadelphia, with support from the Prostate Cancer Foundation.

Seda are proud and honoured to be part of the CellCentric team, with Marcel as our key representative.

“This has been a massive team effort to get to here, a key milestone.  Thank you to all our collaborative scientists, CROs, suppliers, service providers, advisors, consultants, partner hospitals and funders” – Will West, CEO CellCentric

For more details please see CellCentric’s press release.